Key facts
- Revolution Medicines' experimental pancreatic cancer treatment doubled patients' life expectancy in late-stage trials.
- Eli Lilly's experimental anti-obesity drug showed weight reduction comparable to bariatric surgery in trials.
- Recent progress in medicine is attributed to 50 years of cumulative scientific investment and research.
- Cutting-edge curative drugs like gene therapies can have multi-million dollar price tags.
- New anti-obesity drugs require indefinite use to maintain benefits and are expensive.
- An experimental drug for multiple myeloma showed a 100% response rate in early trials.
- An experimental gene-editing therapy showed potential for one-time cholesterol reduction.
- A hepatitis B treatment was found to be a functional cure for 20% of patients in late-phase trials.
Decades of investment in scientific research are now translating into significant medical advancements, with recent announcements of promising breakthroughs against cancers and other serious conditions. Revolution Medicines' experimental treatment for pancreatic cancer, for instance, doubled patients' life expectancy in late-stage clinical trials, extending median overall survival to 13.2 months from 6.7 months compared to standard chemotherapy. This drug targets a mutation found in other cancers as well. Eli Lilly has also reported positive results for an experimental anti-obesity drug that reduced body weight to levels approaching those seen with bariatric surgery. Experts like Zeke Emanuel, an oncologist, and former FDA commissioner David Kessler, emphasize that these developments are the result of 50 years of cumulative scientific effort and investment, rather than a sudden increase in intelligence. However, many of these cutting-edge therapies, including gene therapies and new anti-obesity drugs, come with extremely high price tags and often manage diseases by extending life rather than offering a complete cure. This necessitates ongoing, expensive medical care. The next frontier in medicine aims to achieve earlier detection, complete cures, and effective prevention strategies. Early-stage trial results for an experimental gene-editing therapy show potential for a one-time permanent reduction in cholesterol levels, and a hepatitis B treatment has demonstrated a 'functional cure' in a portion of patients.